Ceapro Inc. Announces Publication of Positive Results for CoQ10-Infused PGX-Treated Alginates in The Journal of Supercritical Fluids

Ceapro inc.

– PGX technology continues to demonstrate its ability to generate new, superior bioactive delivery systems

– Results from the collaborative project with the University of Alberta illustrate how aerogels generated using PGX technology can be uniformly loaded with a fat-soluble active to generate superior bioactive delivery systems

EDMONTON, Alta., Aug. 09, 2022 (GLOBE NEWSWIRE) — Ceapro inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”)a growth-stage biotechnology company focused on the development and commercialization of active ingredients for the health and cosmetics industries, today announced that positive results from a collaborative project with researchers from the University of Alberta have been accepted for publication in The Journal of Supercritical Fluids in an article titled “Supercritical Adsorbent Precipitation of Coenzyme Q10 on Sodium Alginate Airgel,» written by Zixiang Liu, Ricardo Couto, Bernhard Seifried, Byron Yépez, Paul Moquin and Feral Temelli.

The data reported in this peer-reviewed publication comes from the extensive three-year collaborative project completed in April 2021 under the direction of Dr. Feral Temelli from the University of Alberta. Although this screening program generated a wealth of data and information on many PGX-treated biopolymers, sodium alginate (SA), an extract of brown seaweed, was singled out as the most promising candidate for include in the Ceapro pipeline. The results of work investigating the effect of PGX processing parameters and scaling on the physicochemical properties of PGX-SA as a novel stand-alone bioaerogel were published in May 2022. However, the results of this paper demonstrate that PGX-SA can be homogeneously and more easily loaded with an even higher amount of coenzyme Q10 (CoQ10) than other biopolymers previously treated with PGX using supercritical adsorption precipitation.

Investigators also determined that CoQ10 finely deposits on PGX-SA in an amorphous form and forms a stable dispersion in water. Since the amorphous form of CoQ10 is considered to be more bioavailable, it was concluded that PGX-SA could be used to generate more potent CoQ10 supplements. This is an important finding since CoQ10 plays an essential role in maintaining cellular functions and energy production in humans and according to some reports adequate supplementation is recommended after the age of 40. . Until now, adequate CoQ10 supplementation has been difficult due to the hydrophobic nature of CoQ10 and the reported low bioavailability of most commercial CoQ10 supplements. The results demonstrated in this in vitro The study, along with upcoming expected results from an ongoing animal bioavailability study being conducted at the University of Alberta, will determine whether Ceapro can solve this problem.

“We are very pleased with these results, as they will allow Ceapro to expand its pipeline and develop PGX-treated alginate on its own and/or in combination with CoQ10 or other bioactives to form new chemical complexes. which can act as delivery systems in different delivery forms. While PGX-processed alginate is poised to become a key commercial strategic asset for the company along with yeast beta-glucan, the results of this study could lead to the development of many other, more potent delivery systems allowing Ceapro to develop into a high-end life. Scientific enterprise,” said Gilles Gagnon, M.Sc., MBA, President and Chief Executive Officer.

About Pressurized Gas eXpanded Liquid Technology (PGX)

Ceapro’s patented Pressurized Gas eXpanded (PGX) technology is a unique and disruptive technology that has several key advantages over conventional drying and purification technologies that can be used to transform biopolymers into high value-added, structurally fine and open-pore and new biocomposites. PGX is ideally suited for processing high molecular weight water-soluble biopolymers. It has the ability to continuously fabricate ultra-lightweight and highly porous polymer structures, which is not possible with today’s conventional technologies. PGX was invented by Dr. Feral Temelli of the Department of Agricultural, Food and Nutritional Sciences at the University of Alberta (U of A) with Dr. Bernhard Seifried, now Senior Director of Engineering Research and Technology at Ceapro. The U of A license gives Ceapro exclusive worldwide rights for all industrial applications.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable resources. Ceapro adds additional value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutic products for humans and animals. The Company has a wide range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug delivery solutions. For more information about Ceapro, please visit the company’s website at www.ceapro.com.

For more information contact:

jenene thomas
Investor Relations and Corporate Communication Advisor
T (US): +1 (833) 475-8247
E : [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Jacob L. Thornton